153 related articles for article (PubMed ID: 23396551)
1. Effects of antihypertensive therapy on glucose, insulin metabolism, left ventricular diastolic dysfunction and renin system in overweight and obese hypertensives.
De Rosa ML; Musella F; Ilardi F; D'Amore C; Luciano R; Maresca F
J Renin Angiotensin Aldosterone Syst; 2014 Jun; 15(2):196-204. PubMed ID: 23396551
[TBL] [Abstract][Full Text] [Related]
2. Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: A randomized, double-blind, controlled study of 21 obese hypertensives.
Kuperstein R; Sasson Z
Circulation; 2000 Oct; 102(15):1802-6. PubMed ID: 11023935
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
[TBL] [Abstract][Full Text] [Related]
4. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
[TBL] [Abstract][Full Text] [Related]
5. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Jordan J; Engeli S; Boye SW; Le Breton S; Keefe DL
Hypertension; 2007 May; 49(5):1047-55. PubMed ID: 17353513
[TBL] [Abstract][Full Text] [Related]
6. Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension.
Engeli S; May M; Nussberger J; Danser AHJ; Dole WP; Prescott MF; Dahlke M; Stitah S; Pal P; Boschmann M; Jordan J
J Am Soc Hypertens; 2017 Aug; 11(8):488-497. PubMed ID: 28666704
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
[TBL] [Abstract][Full Text] [Related]
8. Aliskiren improves blood pressure control and prevents cardiac damage in high-risk hypertensive subjects.
Mazza A; Montemurro D; Zuin M; Schiavon L; Zorzan S; Chondrogiannis S; Ferretti A; Ramazzina E; Rubello D
Minerva Cardioangiol; 2013 Aug; 61(4):461-9. PubMed ID: 23846012
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome.
Krone W; Hanefeld M; Meyer HF; Jung T; Bartlett M; Yeh CM; Rajman I; Prescott MF; Dole WP
J Hum Hypertens; 2011 Mar; 25(3):186-95. PubMed ID: 20376075
[TBL] [Abstract][Full Text] [Related]
10. Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients.
Boschmann M; Nussberger J; Engeli S; Danser AH; Yeh CM; Prescott MF; Dahlke M; Jordan J
J Hypertens; 2012 Mar; 30(3):561-6. PubMed ID: 22278138
[TBL] [Abstract][Full Text] [Related]
11. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial.
Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Bush C; Keefe DL
J Hypertens; 2009 Jul; 27(7):1493-501. PubMed ID: 19444142
[TBL] [Abstract][Full Text] [Related]
12. Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.
Abe M; Suzuki H; Okada K; Maruyama N; Inoshita A; Baba S; Takashima H; Soma M
Heart Vessels; 2013 Jul; 28(4):442-52. PubMed ID: 22618635
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of a renin inhibitor versus a thiazide diuretic on arterial stiffness and left ventricular diastolic function in elderly hypertensive patients.
Okada Y; Shibata S; Fujimoto N; Best SA; Levine BD; Fu Q
Am J Physiol Regul Integr Comp Physiol; 2017 Oct; 313(4):R400-R409. PubMed ID: 28724547
[TBL] [Abstract][Full Text] [Related]
14. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B;
Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265
[TBL] [Abstract][Full Text] [Related]
15. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively.
Stanton AV; Dicker P; O'Brien ET
Am J Hypertens; 2009 Sep; 22(9):954-7. PubMed ID: 19556972
[TBL] [Abstract][Full Text] [Related]
16. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.
Morishita Y; Hanawa S; Chinda J; Iimura O; Tsunematsu S; Kusano E
Hypertens Res; 2011 Mar; 34(3):308-13. PubMed ID: 21124333
[TBL] [Abstract][Full Text] [Related]
17. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
18. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
[TBL] [Abstract][Full Text] [Related]
19. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
[TBL] [Abstract][Full Text] [Related]
20. Renin inhibition in hypertension.
Gradman AH; Kad R
J Am Coll Cardiol; 2008 Feb; 51(5):519-28. PubMed ID: 18237679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
